MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
CJ Caunt, MJ Sale, PD Smith, SJ Cook - Nature reviews. Cancer, 2015 - europepmc.org
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith, SJ Cook - Nature Reviews Cancer, 2015 - go.gale.com
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
[PDF][PDF] MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith, SJ Cook - NATURE REVIEWS …, 2015 - academia.edu
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
[引用][C] MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith, SJ Cook - Nature Reviews Cancer, 2015 - cir.nii.ac.jp
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith… - Nature Reviews …, 2015 - researchportal.bath.ac.uk
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith… - Nature reviews …, 2015 - pubmed.ncbi.nlm.nih.gov
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
[PDF][PDF] MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith… - NATURE REVIEWS …, 2015 - researchgate.net
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …